DelveInsight reports that over 10 prominent companies are actively engaged in the development of more than 10 therapeutic candidates for the treatment of brain cancer.
Brain Cancer Overview:
Brain metastases in cancer are typically linked to poor clinical outcomes. Younger patients and those with estrogen receptor-negative, HER2-positive, or basal-like breast cancer subtypes face a heightened risk of developing brain metastases. Magnetic resonance imaging (MRI) is the standard diagnostic tool, while biopsies are occasionally performed for confirmation. Other diagnostic techniques include neuroimaging, disease staging, and neuropathological analysis.
Treatment usually consists of whole-brain radiation therapy, or a combination of stereotactic radiosurgery or surgical resection followed by whole-brain radiation. Nonetheless, the one-year survival rate remains low, at approximately 20%. A major hurdle in treatment is the blood-brain barrier, which limits the delivery of many chemotherapeutic agents. Despite this, some therapies show promise—etirinotecan pegol has demonstrated efficacy as a chemotherapeutic option, and targeted agents like abemaciclib are gaining ground. Lapatinib, a small molecule known to penetrate the blood-brain barrier, has been extensively evaluated for its role in treating HER2-positive brain metastases.
Request for a detailed insights report on Brain Cancer pipeline insights
“Brain Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Brain Cancer Therapeutics Market.
Key Takeaways from the Brain Cancer Pipeline Report
-
DelveInsight’s Brain Cancer pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Brain Cancer treatment.
-
In December 2024, Kazia Therapeutics’ stock dropped by 26%, falling to $2.28, after the FDA indicated it might only approve the company’s brain cancer treatment, paxalisib, through standard approval rather than granting accelerated approval. This decline followed a 48% decrease in the stock’s value earlier in the year. Paxalisib, designed to treat glioblastoma, showed significant improvements in overall survival in a July trial, which had previously caused a surge in the company’s stock price.
-
In April 2024, the US FDA granted accelerated approval to Day One Biopharmaceuticals’ OJEMDA (tovorafenib) for treating patients aged 6 months and older with certain relapsed or refractory pediatric low-grade glioma.
-
In April 2024, TME Pharma received Fast Track Designation from the US FDA for NOX-A12 (olaptesed pegol), a CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for the treatment of glioblastoma, an aggressive form of adult brain cancer.
-
In February 2024, Servier announced that the US FDA had accepted the filing and granted priority review for the New Drug Application (NDA) for vorasidenib. If approved, vorasidenib would become the first targeted therapy for patients with IDH-mutant gliomas, with a Prescription Drug User Fee Act (PDUFA) action date set for August 20, 2024.
-
Key Brain Cancer companies such as Angiochem Inc, Novartis, Merck Sharp & Dohme Corp., AstraZeneca, Criterium, Inc., Bristol-Myers Squibb, Bayer, Northwest Biotherapeutics, Array BioPharma, and others are evaluating new drugs for Brain Cancer to improve the treatment landscape.
-
Promising Brain Cancer pipeline therapies in various stages of development include ANG1005, Pembrolizumab, and others.
Brain Cancer Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Brain Cancer Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Brain Cancer treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Brain Cancer market.
Download our free sample page report on Brain Cancer pipeline insights
Brain Cancer Emerging Drugs
-
ANG1005: Angiochem
-
Pembrolizumab: Merck Sharp & Dohme
Brain Cancer Companies
More than 10 leading companies are actively developing treatments for brain metastases originating from breast cancer. Among them, Angiochem has the most advanced drug candidates, currently in Phase III clinical trials.
DelveInsight’s report covers around 10+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Brain Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Brain Cancer Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Brain Cancer Therapies and Key Companies: Brain Cancer Clinical Trials and advancements
Brain Cancer Pipeline Therapeutic Assessment
• Brain Cancer Assessment by Product Type
• Brain Cancer By Stage
• Brain Cancer Assessment by Route of Administration
• Brain Cancer Assessment by Molecule Type
Download Brain Cancer Sample report to know in detail about the Brain Cancer treatment market @ Brain Cancer Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Brain Cancer Current Treatment Patterns
4. Brain Cancer – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Brain Cancer Late-Stage Products (Phase-III)
7. Brain Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Brain Cancer Discontinued Products
13. Brain Cancer Product Profiles
14. Brain Cancer Key Companies
15. Brain Cancer Key Products
16. Dormant and Discontinued Products
17. Brain Cancer Unmet Needs
18. Brain Cancer Future Perspectives
19. Brain Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Brain Cancer Pipeline Reports Offerings
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/